Hindustan Unilever Limited



11th August 2020

| Stock Data | | |
|------------------|------------|--|
| CMP (₹) | 2216 | |
| TARGET (₹) | 2500 | |
| Upside | 13% | |
| M.Cap (₹ in cr) | 520760 | |
| Equity (₹ in cr) | 235 | |
| 52 wk H/L ₹ | 2614/1756 | |
| Face Value ₹ | 1 | |
| Div Yield | 1.15% | |
| NSE Code | HINDUNILVR | |
| BSE Code | 500696 | |

| Valuation Data | |
|----------------|-------|
| P/E | 71.6 |
| P/BV | 51.43 |
| BV | 43.09 |

| Key Finai | ncial Data |
|---------------------|------------|
| Net Worth (₹ in cr) | 10127 |
| EPS(TTM) | 30.95 |

| Index Detail | | |
|--------------|----------|--|
| Sensex | 38407.01 | |
| Nifty | 11322.50 | |

LEAD RATIONALE

Amid the pandemic induced global chaos, one thing is at least clear: a few powerful and quality companies are set to gain more clout and HUL is one such name. With key brands in its bucket, solid quarter(Q1FY21) along with synergy benefits after the merger of GSK consumer, acquisition of Vwash brand HUL is well poised for future growth.

Its 80% of the portfolio saw 6% growth during the quarter & is gaining market share as well. **As 40% of the sale is from rural areas- Government focus towards improving demand in rural areas would expand sales further.**

Witnessed solid performance across the household care and fabric wash. Penetration gains lead to strong growth across home & hygiene portfolio. Followed by uptick in demand for sanitizers & hand wash there was a strong double-digit growth across formats led by Lifebuoy.

As consumption has been shifted to in-house during lock-down, demand for Tea & coffee surged- delivered double digit growth. Growing consumers interest around wellness space & immunity- augurs well going ahead.

The **ice cream, food solutions and vending** got severely impacted due to out of home consumption loss. **Pureit** which took a massive hit from both business and servicing prospective, is now picking up.

Also, mobility restrictions had impacted discretionary categories such as **haircare**, **skincare** and **colour cosmetics**. But, as supply issues have improved by the end of Q1, the demand for skincare & deodorants have started picking up.

Now, HUL is operating with shorter planning cycles and working on longer shifts to rapidly fill up the gap in supply chain and is heading towards normalcy.

Hindustan Unilever Limited



Acquired intellectual property rights including trademarks, design and knowhow related to the **VWash brand** worldwide. **Vwash** is the market leader in intimate Hygiene category which gives HUL entry into the female intimate hygiene segment (VWash has more than 50% market share in the segment). **It is looking to scale up the brand by building awareness, driving penetration, leveraging distribution and enhance offering for chemist channel.** Moreover, post this pandemic the growing need for health & hygiene would significantly add up to revenue.

Going ahead, company will focus on hygiene, cleaning and nutrition as per the demand. Expansion, especially in the nutrition category would further unlock growth potential. *In the near term, the volatility in input costs to remain. The liquidity pressure would continue to remain uplifted.*

The demand for brands- Lifebuoy, Domex, Horlicks and Red lable has remained elevated.

April-June was the period of restoring of operations. September Quarter will give a clear picture of underlying demand. Management stated that "Our B2B sales ordering app Shikar and our hyperlocal ordering platform of Humara Shop have witnessed increased adoption and usage by trade and consumers during the lockdown".

The behavioral change for personal healthcare and hygiene has significantly improved and going forward even post the pandemic, people would be much more cautious about being hygienic and thereby the demand for sanitizers and personal care would remain elevated.

The GSK merger effective 1st April,2020 brings in iconic brands and ~3500 strong nutrition team in HUL fold.

Moreover, merger with GSK offers double digit potential for medium-long term with future margin potential of 550-700bps(of 800-1000bps already 250-300bps synergy has been realized). Brands such as Horlicks and Boost would provide opportunity to drive premiumization and would leverage HUL distribution capabilities. Hence, we expect good recovery in Revenue & margins ahead.

Fundamentally too, it is virtually debt-free. Has sound ROE at 85.62%. We recommend to BUY for a price target of ₹ 2500 in medium term.

Hindustan Unilever Limited



In the homecare care segment, as crude oil prices remain lower, HUL has passed the benefits to consumers by price cuts of approx. 15% (in lifebuoy hand wash & Domex). However, in nutrition and tea portfolio price hike has been done.

Health, Hygiene & Nutrition



Discretionary and supply constrained



Out of home



Factories & warehouses re-opens, capacity utilization now at 90%

Due to pandemic & lockdown all the factories and warehouses remained shut which impacted production and sales for short term. With unlocking all over, HUl resumed its capacities except one in Assam. Hence, HUL's capacity utilization now stands at 90% against pre-covid levels- bodes well for the company. The production levels which were halted during March has moved to 40% levels in April and 80%in May- higher than the industry average.

Already the demand for hand sanitizers, handwash, hygiene and nutrition products are on surge. Company is also making efforts to re-evaluate cost, looking for opportunities of cash generation and curtail further disruptions in supply chain.

Hindustan Unilever Limited



Turnaround in operations


Portfolio prioritization

D.8X 0.8X 0.5X 0.2X 0.3X 0.3X 0.3X 0.4 Date Present Plan Number of SKUs


Capacity unlocks




New demand capture & fulfilment models



Addressing the consumer needs during COVID, company has ramped up capacities. Its 86% business is wining the share.





Hindustan Unilever Limited



Merger with GSK- to unlock future growth potential

Merger with GSK open up huge opportunities in the Nutrition portfolio. The GSK merger effective 1st April,2020 brings in iconic brands and ~3500 strong nutrition team in HUL fold.

The deal is set for a mega Rs 31700cr & additionally Rs 3045cr to acquire the Horlicks brand for India– *Horlicks has a volume share close to 50%*. GSKCH's brands such as Horlicks, Boost, and Maltova will now be part of the company's food and refreshments business falling under the nutrition category. Under the deal, HUL will distribute GSK's brands like **Eno, Crocin, Sensodyne etc in the country for 5 years**.

GlaxoSmithKline Consumer Healthcare Limited business delivered a total turnover of Rs 45 billion in FY19, mainlt through the Horlicks & Boost. The exchange ratio of the merger has ben set at 4.39 HUL shares for each GSK share. Post the completion, GSK Plc (including group companies) will own 5.7% of the merged entity; while Unilever shareholding in the combined company will be 61.9% versus 67.2% prior to the merger.

GSKCH business—or the nutrition portfolio—will now function as part of its food and refreshments (F&R) business segment. This merger is in line with the strategy to build a sustainable and profitable F&R business in India by leveraging the megatrend of health & wellness. It will be classified as a separate category country business team (CCBT). That team will look at unlocking the opportunity in the HFD segment. The nutrition business head will lead a CCBT and a integration team that will work over the next 18 months to draw out synergy plans, create business processes and IT harmonization, likely to be completed by June FY2021.



Nutrition a separate CCBT within F&R Division

Business strategy & execution – Unlock the market development opportunity



Integration team continues for next 18 months


- · Charting of synergy plans
- Business Process and IT Harmonisation full IT integration likely to be completed by June 2021


Λ...

Hindustan Unilever Limited



Merger details





Growth Drivers:

- ➤ 25% of India's population is under the age of 14 years.
- ➤ 1 out of 3 children are too short for their age
- ➤ 1 out of 4 Indian adolescents are too thin for their age
- ➤ 9 in 10 children's diets are deficient in micro nutrients.
- ➤ Rural penetration offers significant growth potential As per report(FY19), Rural penetration for Health food Drink in South & East accounts for only 28% and 26% which offers more room for upside.

Hindustan Unilever Limited



The GTM (Go-to-Market) ramp-up offers significant growth opportunity. During lockdown, company's products have witnessed a significant increase in adoption by consumers from the B2B sales ordering app Shikar and hyperlocal ordering platform Humara Shop. Thus, it gives company an opportunity to cover more stores and maximize physical reach for its products.

Key plans to unlock value

- » Business process transformation
- » Rewiring Nutrition (SAP)
- » Go to Market Synergies
- » Capacity and Cost Synergies
- » Functional Integration
- » Talent and Culture

Fuel for growth

- ⇒ Dynamic re-allocation of spends to optimize ROI
- ⇒ Reduction in non-essential spends
- ⇒ Realise year 1 synergy benefits from nutrition integration
- ⇒ Dial up savings across value chain; leverage scale

Key Performance-Q1FY20-21

Strong Quarter despite challenging business environment

Revenue growth reported at 4.4% at ₹ 10560cr during Quarter, attributable to the merger of GSK nutrition brands. Excluding the impact of merger, Domestic Consumer Growth declined 7% due to pandemic and lockdown.

Profit before tax (PBT) for the period fell 6% (Y-O-Y) to ₹ 2,411 cr. While Net profit rose 7.2% YoY to ₹ 1,881 cr

Operating profit, however, fell 0.1% to ₹ 2,644 cr in Q1, while operating margins narrowed to 25% from 26.2% a year ago.

Hindustan Unilever Limited



| Segment Revenue | Home care | Beauty & personal care | Food & re- freshment |
|---------------------------|-----------|------------------------|-------------------------|
| Revenue- Q1FY20-21 | 3392 | 4039 | 2958 |
| Segment Revenue growth | -2% | -12% | 52% |
| Segmental Margins | 19% | 28% | 20% |

₹in cr Heath, Hygiene and Nutrition constituting 80% of portfolio delivered healthy mid-single digit domestic consumer growth. Immunity boosting Horlicks with added Zinc was launched in the quarter.

> Household Care grew strongly on back of penetration led gains.

> Domex's credentials of destroying

Coronavirus in just 60 seconds is resonating well with consumers. In Fabric Wash, Surf excel ran a contextual campaign #DaagGharPeRahenge. Skin Cleansing led by Lifebuoy delivered strong double-digit growth across formats.

Has significantly stepped up capacities in both hand wash and hand sanitizers to meet the consumer needs. Lifebuoy is making the 'good habit of handwashing' viral with campaigns across platforms.

Oral Care delivered good performance with accelerated momentum on **CloseUp.** In **Hair Care**, pickup in consumer demand in the latter part of the quarter. *Performance of Skin, Color Cosmet*ics and Deos being relatively discretionary in nature was impacted severely on account of supply led issues and closure of some of the channels that are extremely relevant for the categories.

Riding on the 'In-home, wellness and immunity' trends, Foods, Tea and Coffee delivered strong performance with double digit growths. Red Label extended its long-running 'Taste of Togetherness' campaign.

80% business registered a growth rate of 6 %.

The nutrition business, including GSK Consumer's products, registered 5% growth.

The discretionary portfolio, including skincare, deos and colour cosmetics declined 45%

Out-of-home consumption, which includes ice creams, declined 70%

80% portfolio focused on Health, hygiene & nutrition 15% is discretionary 5% is out-of-home consumption

Hindustan Unilever Limited



Result Update:

Rs. Crores

| Particulars | JQ'20 | JQ'19 | Growth % |
|---------------------------------------|--------|-------|----------|
| Sales | 10,406 | 9,984 | 4%* |
| EBITDA | 2,644 | 2,647 | Flat |
| Other Income (Net) | 127 | 123 | |
| Exceptional Items - Credit / (Charge) | (118) | 7 | |
| РВТ | 2,411 | 2,563 | - 6% |
| Tax | 530 | 808 | |
| PAT bei | 1,873 | 1,751 | 7% |
| Net Profit | 1,881 | 1,755 | 7% |

- *Domestic Consumer Growth at 7%
- Exceptional items include costs related to Nutrition business merger and integration

Share Price chart:



Hindustan Unilever Limited



Disclosures:

Business Activity:

Rudra Shares & Stock Brokers Limited is engaged in the business of providing broking services & distribution of various financial products. RUDRA is also registered as a Research Analyst under SEBI(Research Analyst) Regulations, 2014. SEBI Reg. No. INH100002524.

Disciplinary History:

There has been no instance of any Disciplinary action, penalty etc. levied/passed by any regulation/administrative agencies against RUDRA and its Directors. Pursuant to SEBI inspection of books and records of Rudra, as a Stock Broker, SEBI has not issued any Administrative warning to Rudra.

Terms & Conditions of issuance of Research Report:

The Research report is issued to the registered clients. The Research Report is based on the facts, figures and information that are considered true, correct and reliable. The information is obtained from publicly available media or other sources believed to be reliable. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation to buy or sell or subscribe for securities or other financial instruments for clients.

Disclosures with regard to ownership and material conflicts of interest: Rudra or its research analysts, or his/her relative or associate has any direct or

| reduce of its research analysis, of mis/not relative of associate has any affect of | |
|---|----|
| Indirect financial interest in the subject company. | NO |
| Rudra or its research analysts, or his/her relative or associate has any other | |
| material conflict of interest at time of publication of the research report. | NO |
| Rudra or its research analysts, or his/her relative or associates have actual | |
| ownership of one per cent or more securities of the subject company. | NO |
| | |
| Disclosures with regard to receipt of compensation: | |
| Rudra or its associates have received any compensation from the subject | |
| company in the past twelve months. | NO |
| Rudra or its associates have managed or co-managed public offering of | |
| securities for the subject in the past twelve months. | NO |
| Rudra or its associates have received any compensation or other benefits | |
| from the subject company or third party in connection with the | |
| research report. | NO |
| | |

Hindustan Unilever Limited



Other Disclosures:

The research analyst has served as an officer, director, employee of the subject company.

Rudra or its research analyst has been engaged in market making activity for the subject company.

Rudra or its or associates have received any compensation from the subject company in the past twelve months.

NO

Disclaimers:

This Research Report (hereinafter called report) has been prepared and presented by RUDRA SHARES & STOCK BROKERS LIMITED, which does not constitute any offer or advice to sell or does solicitation to buy any securities. The information presented in this report, are for the intended recipients only. Further, the intended recipients are advised to exercise restraint in placing any dependence on this report, as the sender, Rudra Shares & Stock Brokers Limited, neither guarantees the accuracy of any information contained herein nor assumes any responsibility in relation to losses arising from the errors of fact, opinion or the dependence placed on the same.

Despite the information in this document has been previewed on the basis of publicly available information, internal data, personal views of the research analyst(s) and other reliable sources, believed to be true, we do not represent it as accurate, complete or exhaustive. It should not be relied on as such, as this document is for general guidance only. Besides this, the research analyst(s) are bound by stringent internal regulations and legal and statutory requirements of the Securities and Exchange Board of India(SEBI) and the analysts' compensation was, is, or will be not directly or indirectly related with the other companies and/or entities of Rudra Shares & Stock Brokers Ltd and have no bearing whatsoever on any recommendation, that they have given in the research report. Rudra Shares & Stock Brokers Ltd or any of its affiliates/group companies shall not be in any way responsible for any such loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Rudra Shares & Stock Brokers Ltd has not independently verified all the information, which has been obtained by the company for analysis purpose, from publicly available media or other sources believed to be reliable. Accordingly, we neither testify nor make any representation or warranty, express or implied, of the accuracy, contents or data contained within this document. Rudra Share & Stock Brokers Ltd and its affiliates are engaged in investment advisory, stock broking, retail & HNI and other financial services. Details of affiliates are available on our website i.e. www.rudrashares.com.

We hereby declare, that the information herein may change any time due to the volatile market conditions, therefore, it is advised to use own discretion and judgment while entering into any transactions, whatsoever.

Individuals employed as research analyst by Rudra Shares & Stock Brokers Ltd or their associates are not allowed to deal or trade in securities, within thirty days before and five days after the publication of a research report as prescribed under SEBI Research Analyst Regulations.

Subject to the restrictions mentioned in above paragraph, we and our affiliates, officers, directors, employees and their relative may: (a) from time to time, have long or short positions acting as a principal in, and buy or sell the securities or derivatives thereof, of Company mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or profits.